HRSA Updates 340B Drug Discounts Enrollment Process for Feedback
Published Date: 1/8/2026
Notice
Summary
The Health Resources and Services Administration (HRSA) is updating how hospitals and clinics sign up and renew their participation in the 340B Drug Pricing Program, which helps them get medicines at lower prices. They’re asking for public feedback by February 9, 2026, before finalizing these changes. This update aims to keep the process smooth and fair, with no big cost changes expected for the entities involved.
Analyzed Economic Effects
7 provisions identified: 5 benefits, 2 costs, 0 mixed.
Estimated Total Annual Administrative Burden
HRSA estimates the total annualized burden for this information collection is 74,248 hours across 46,183 respondents and 139,251 total responses. Specific items include 48,136 hours for contracted pharmacy registrations and 8,772 hours for hospital annual recertifications, among others.
New STD/TB Documentation Requirement
If you are an STD or TB grantee enrolling or recertifying in the 340B Program, you must provide supporting documentation such as a federal grant notice of award (grantor, grant number, period of funding, recipient) and, for subgrantees, an executed subrecipient agreement. HRSA says this will slightly increase the administrative burden (average burden for some collections increased from 1.0 to 1.25 hours).
Shipping Address Clarification
HRSA added clearer shipping-address questions in the 340B registration system to identify whether an address is a pharmacy, a health care delivery site, or another receiving location. HRSA says this should make reviews more efficient and will not significantly change the burden on covered entities.
Family Planning Time-Period Field Added
Family Planning (Title X) covered entities must now report the time period when assistance was received during 340B registration and recertification. HRSA says this is a minor addition and will not significantly increase burden because the time period is readily available.
Tribal Agreement Number Collection
Urban Indian and Tribal Contract/Compact (FQHC628/FQHC638) covered entities must provide their Tribal Agreement number in OPAIS during registration and recertification to help verify eligibility. HRSA says this will not significantly increase burden.
Hospital Form Language Clarifications
HRSA revised hospital registration fields (e.g., changing 'File Date' to 'Date/Time Prepared' and 'Medicare Provider Number' to 'CMS Certification Number'), clarified Worksheet S submission (signed, dated, encrypted copy), and trial balance instructions to reduce confusion. HRSA says these changes do not change burden on hospitals.
No Changes for Contract Pharmacies, PPA, Pricing
HRSA states there are no changes to Contract Pharmacy Certification, the Pharmaceutical Pricing Agreement (PPA) and addendum, or Pricing Data Submission/Validation/Dissemination from prior submissions. HRSA says there is no change in burden on manufacturers or contract pharmacies.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16396, National Newborn Screening Stakeholder Workgroup
HRSA provides funding to support a national center for newborn screening systems known as the National Center for Newborn Screening Systems Excellence (NBS Excel). In fiscal year 2026, supplemental funding is being provided to NBS Excel to establish a national newborn screening stakeholder workgroup. This workgroup will be a pathway for conditions to be considered and recommended for inclusion in the Recommended Uniform Screening Panel (RUSP) and to discuss national- level issues related to newborn screening. Membership will include representatives from a wide range of newborn screening experts and stakeholders. The award recipient will convene the workgroup and develop findings, reports, and recommendations for HRSA's review and consideration. HRSA will then make recommendations to the Secretary of Health and Human Services, who has final decision-making authority on updates to the RUSP.
2026-16227, Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Transforming Pediatrics for Early Childhood Program Performance Measures
In compliance with the Paperwork Reduction Act of 1995, HRSA submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period. OMB may act on HRSA's ICR only after the 30-day comment period for this notice has closed.
2026-16054, Agency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Organ Procurement and Transplantation Network Board of Directors and Committee Member Applications and Forms
In compliance with the requirement for opportunity for public comment on proposed data collection projects of the Paperwork Reduction Act of 1995, HRSA announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.
2026-15596, Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; National Health Service Corps Scholar/Students to Service Travel Worksheet, OMB No. 0906-0087-Revision
In compliance with the Paperwork Reduction Act of 1995, HRSA submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period. OMB may act on HRSA's ICR only after the 30-day comment period for this notice has closed.
2026-15633, Notice Regarding 340B Rebate Model Pilot Program
The U.S. Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), Office of Pharmacy Affairs (OPA), which administers the 340B Drug Pricing Program (340B Program), is issuing this Notice to announce the availability of a revised 340B Rebate Model Pilot Program (Pilot). The Pilot provides a rebate mechanism through which qualifying drug manufacturers may effectuate the 340B ceiling price for certain drugs sold to covered entities. Consistent with HRSA's longstanding statutory authority, rebates will be used instead of upfront discounts. HRSA issued a Request for Information (RFI) \1\ to gather input from interested parties regarding the potential use of rebates to effectuate the ceiling price under the 340B Program, including the standards and procedures that should govern the approval of manufacturer rebate plans and the impacts on all stakeholders. After carefully considering all comments from interested parties and different policy alternatives, HRSA is announcing this Pilot, which will implement a rebate approach for a limited set of drugs, and which builds on established and successful rebate programs. ---------------------------------------------------------------------------
2026-15221, Agency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Applicant Organizational National Provider Identifiers and Centers for Medicare & Medicaid Services Certification Numbers Form
In compliance with the requirement for opportunity for public comment on proposed data collection projects of the Paperwork Reduction Act of 1995, HRSA announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.
Previous / Next Documents
Previous: 2026-00177, Lightweight Thermal Paper From China; Determinations
The U.S. International Trade Commission decided to keep special taxes on lightweight thermal paper imported from China. This move protects American businesses from harm and means these taxes won’t go away anytime soon. Companies importing this paper should expect these duties to continue, affecting prices and trade starting now.
Next: 2026-00181, Certain Hot-Rolled Steel Flat Products From the Republic of Korea: Preliminary Results and Rescission, In Part, of Antidumping Duty Administrative Review; 2023-2024
The U.S. found that some hot-rolled steel from Korea was sold here cheaper than normal between October 2023 and September 2024. They’re stopping the review for 46 companies that didn’t sell any steel during that time. This could affect import duties and money flows starting January 8, 2026, so companies should pay attention and get ready.